 |
|
|
| |
Efficacy and safety of 8 weeks of elbasvir/grazoprevir in HCV GT4-infected treatment-naive participants
|
| |
| |
Reported by Jules Levin
EASL 2018 - International Liver Congress Paris, France 12 April 2018
Tarik Asselah1; Stanislas Pol2; Christophe Hezode3; Veronique Loustaud-Ratti4; Vincent Leroy5; Si Nafa Si Ahmed6; Violaine Ozenne7; Jean-Pierre Bronowicki8; Dominique Larrey9; Albert Tran10; Laurent Alric11; Eric Nguyen-Khac12; Michael Robertson13; George J. Hanna13; Deborah Brown13; Ernest Asante-Appiah13; Steve Ludmerer13; Feng-Hsiu Su13; Peggy Hwang13; Stephanie Klopfer13;
Frank Dutko13; Amir Guidoum13; Karin Hagen13; Barbara Haber13; Rohit Talwani13; Lawrence Serfaty14
1Hopital Beaujon, Clichy, France; 2AP-HP/Universite Paris Descartes, Paris, France; 3Hopital Henri Mondor, Creteil, France; 4CHU Limoges, Limoges, France; 5CHU Grenoble Alpes, Grenoble, France; 6Centre Hospitalier Regional d' Orleans, Orleans, France; 7Hopital Saint Antoine, Paris, France; 8CHU Nancy, Nancy, France; 9Hopital Saint Eloi, Montpellier School of Medicine, Montpellier, France; 10Hopital de l'Archet II, Nice, France; 11CHU Toulouse, Toulouse, France; 12CHU Amiens, Amiens, France; 13Merck & Co., Inc., Kenilworth, NJ, USA; 14Hopital de Hautepierre, Universitaires de Strasbourg, Strasbourg, France
|
| |
|
|
|
|
|
